Efung Capital

Efung Capital is a Chinese venture capital firm active in healthcare and biotech investing, though elsewhere's corpus captures it primarily through its co-investment activity alongside Gaorong Ventures rather than direct profile coverage. It appears as a co-lead investor in Westlake Omics' Pre-A round in January 2022 alongside Hillhouse Venture Capital, with Gaorong Ventures following in that deal , and as a participant in Andao Pharma's $50 million Series B in late 2021 and subsequent Series C in late 2025 . The firm also shows up in other biotech financings including Andon Therapeutics' Series C, suggesting a focus on life sciences rather than a generalist mandate — but elsewhere's corpus does not cover its founding, team, or fund structure directly.